US10155929B2 - Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA - Google Patents

Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA Download PDF

Info

Publication number
US10155929B2
US10155929B2 US13/893,166 US201313893166A US10155929B2 US 10155929 B2 US10155929 B2 US 10155929B2 US 201313893166 A US201313893166 A US 201313893166A US 10155929 B2 US10155929 B2 US 10155929B2
Authority
US
United States
Prior art keywords
cells
free
feeder
xeno
reprogramming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US13/893,166
Other languages
English (en)
Other versions
US20130302295A1 (en
Inventor
Jiwu Wang
Luigi Warren
Yuhui NI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allele Biotechnology and Pharmaceuticals Inc
Original Assignee
Allele Biotechnology and Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allele Biotechnology and Pharmaceuticals Inc filed Critical Allele Biotechnology and Pharmaceuticals Inc
Priority to US13/893,166 priority Critical patent/US10155929B2/en
Publication of US20130302295A1 publication Critical patent/US20130302295A1/en
Assigned to ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC. reassignment ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NI, Yuhui, WANG, JIWU, WARREN, LUIGI
Priority to SG10202006695TA priority patent/SG10202006695TA/en
Priority to SG11201509368PA priority patent/SG11201509368PA/en
Priority to HK16110689.7A priority patent/HK1222675A1/zh
Priority to EP21154853.2A priority patent/EP3904504A1/en
Priority to MX2015015840A priority patent/MX2015015840A/es
Priority to CN201480033794.XA priority patent/CN105555949A/zh
Priority to EP14801588.6A priority patent/EP2997130A4/en
Priority to JP2016514171A priority patent/JP6971574B2/ja
Priority to US14/292,317 priority patent/US10119150B2/en
Priority to HK16112614.3A priority patent/HK1224335A1/zh
Priority to PCT/US2014/040362 priority patent/WO2014190361A2/en
Priority to MX2021005715A priority patent/MX2021005715A/es
Priority to US16/181,261 priority patent/US10435711B2/en
Publication of US10155929B2 publication Critical patent/US10155929B2/en
Application granted granted Critical
Priority to JP2021121453A priority patent/JP2021166553A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • the target cells are grown at a density of 50 k, 75 k, 100 k, or 150 k cells/well of a standard 6-well plate in a feeder-free surface, whereas the volume of each well is adjusted to be as between 0.5 ml to 5 ml of appropriate medium; b) transfecting cells with varying doses of 50 ng to 800 ng/ml mRNA each time during reprogramming, whereas lower doses are used at earlier time points than later time points; c) attaining iPSCs without passaging.
  • exogenous nucleic acid refers to a nucleic acid that is not normally or naturally found in and/or produced by a cell in nature, and/or that is introduced into the cell (e.g., by electroporation, transfection, infection, lipofection, or any other means of introducing a nucleic acid into a cell).
  • a novel method for highly efficient reprogramming of non-stem cells into pluripotent stem cells by contacting target cells with combinations of engineered reprogramming factors and non-engineered reprogramming factors in such a way that iPSCs can be produced in about 9 days, sometimes as short of 6, or even 5 days. These iPS cells can be produced as feeder-free, xeno-free, and footprint-free iPSCs.
  • the novel technology also differs from all previously known technologies in that the iPSCs so created are “clean” in that they have not been in contact with any virus or vector.
  • Utility of the invention can be found in virtually all areas that involve stem cell establishment, differentiation, utility in cellular and developmental research, as well as clinical applications. Similar procedures can also be useful in directed differentiation or transdifferentiation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US13/893,166 2012-05-13 2013-05-13 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA Active US10155929B2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US13/893,166 US10155929B2 (en) 2012-05-13 2013-05-13 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
PCT/US2014/040362 WO2014190361A2 (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
EP14801588.6A EP2997130A4 (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK16112614.3A HK1224335A1 (zh) 2013-05-13 2014-05-30 使用合成信使rna無飼養層衍生人誘導多能幹細胞
HK16110689.7A HK1222675A1 (zh) 2013-05-13 2014-05-30 使用合成信使rna無飼養層衍生人誘導多能幹細胞
EP21154853.2A EP3904504A1 (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
MX2015015840A MX2015015840A (es) 2013-05-13 2014-05-30 Derivacion sin alimentadores de células madre fluripotentes inducidas humanas con arn mensajero sintético.
CN201480033794.XA CN105555949A (zh) 2013-05-13 2014-05-30 使用合成信使rna无饲养层衍生人诱导多能干细胞
SG10202006695TA SG10202006695TA (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
JP2016514171A JP6971574B2 (ja) 2013-05-13 2014-05-30 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導
US14/292,317 US10119150B2 (en) 2012-05-13 2014-05-30 Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA
SG11201509368PA SG11201509368PA (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
MX2021005715A MX2021005715A (es) 2013-05-13 2015-11-13 Derivacion sin alimentadores de celulas madre pluripotentes inducidas humanas con arn mensajero sintetico.
US16/181,261 US10435711B2 (en) 2012-05-13 2018-11-05 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
JP2021121453A JP2021166553A (ja) 2013-05-13 2021-07-26 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261646292P 2012-05-13 2012-05-13
US13/893,166 US10155929B2 (en) 2012-05-13 2013-05-13 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/292,317 Continuation-In-Part US10119150B2 (en) 2012-05-13 2014-05-30 Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA

Publications (2)

Publication Number Publication Date
US20130302295A1 US20130302295A1 (en) 2013-11-14
US10155929B2 true US10155929B2 (en) 2018-12-18

Family

ID=51939013

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/893,166 Active US10155929B2 (en) 2012-05-13 2013-05-13 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA

Country Status (8)

Country Link
US (1) US10155929B2 (en6)
EP (2) EP3904504A1 (en6)
JP (2) JP6971574B2 (en6)
CN (1) CN105555949A (en6)
HK (2) HK1222675A1 (en6)
MX (2) MX2015015840A (en6)
SG (2) SG10202006695TA (en6)
WO (1) WO2014190361A2 (en6)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10435711B2 (en) * 2012-05-13 2019-10-08 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3260140B1 (en) 2011-12-05 2021-02-03 Factor Bioscience Inc. Methods and products for transfecting cells
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
CN110241087B (zh) * 2012-05-13 2023-02-03 美国绿阳生物技术及医药公司 使用合成的信使rna无饲养细胞地衍生人类诱导性多能干细胞
US10155929B2 (en) * 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
WO2013188679A1 (en) * 2012-06-13 2013-12-19 Stemgent, Inc. Methods of preparing pluripotent stem cells
KR102121086B1 (ko) 2012-11-01 2020-06-09 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
KR102415811B1 (ko) 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
TWI698526B (zh) * 2014-05-30 2020-07-11 美商綠陽生物科技及製藥公司 利用合成之信使ｒｎａ進行之人類誘導型多能幹細胞之無餵養細胞衍化（ｄｅｒｉｖａｔｉｏｎ）
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN105567642B (zh) * 2016-02-01 2019-07-12 中国科学院生物物理研究所 一种着色性干皮病人多能干细胞的制备方法
EP3500585A4 (en) 2016-08-17 2020-04-01 Factor Bioscience Inc. NUCLEIC ACID PRODUCTS AND METHOD FOR ADMINISTRATION THEREOF
WO2018094114A2 (en) 2016-11-16 2018-05-24 Allele Biotechnology & Pharmaceuticals, Inc. Induction of pancreatic beta cells by stem cell differentiation with rna
KR102546749B1 (ko) * 2016-12-28 2023-06-22 교토후고리츠다이가쿠호진 골격근 세포 및 이의 유도 방법
CN107142244B (zh) * 2017-07-03 2019-12-20 广州润虹医药科技股份有限公司 培养基及其用途与诱导多能干细胞向间充质干细胞转化的方法
CN110997706B (zh) 2017-07-13 2024-07-16 美国绿阳生物技术及医药公司 通过利用地标转录因子的干细胞分化诱导神经祖细胞、寡树突细胞祖细胞及寡树突细胞
SG11202008839WA (en) * 2018-03-13 2020-10-29 Univ Leland Stanford Junior Transient cellular reprogramming for reversal of cell aging
EP3806873A1 (en) * 2018-06-16 2021-04-21 Luigi Warren Reprogramming cells with synthetic messenger rna
IL287808B2 (en) 2019-05-14 2024-07-01 Aleph Farms Ltd Pluripotent cell aggregates and use thereof
CN114450265B (zh) 2019-07-03 2024-12-24 菲克特生物科学股份有限公司 阳离子脂质及其用途
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
JP2022104813A (ja) 2020-12-29 2022-07-11 アイ ピース，インコーポレイテッド リプログラミング因子を導入された細胞の培養方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033828B2 (en) 1989-06-22 2006-04-25 The Salk Institute For Biological Studies Nucleic acid encoding gamma retinoic acid receptor fusion protein
US20090191159A1 (en) * 2007-06-15 2009-07-30 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
WO2010057614A1 (en) 2008-11-21 2010-05-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Reprogramming cells toward a pluripotent state
CA2770412A1 (en) * 2009-08-07 2011-02-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2011142832A2 (en) 2010-05-13 2011-11-17 Whitehead Institute For Biomedical Research Stem cells derived under low oxygen conditions
WO2012012708A1 (en) 2010-07-22 2012-01-26 Regents Of The University Of Minnesota Induced pluripotent stem cells
US20120207744A1 (en) 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
WO2013126813A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
US20130302295A1 (en) 2012-05-13 2013-11-14 Allele Biotechnology And Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
WO2013173248A2 (en) 2012-05-13 2013-11-21 Allele Biotechnology And Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG160248A1 (en) * 2008-09-18 2010-04-29 Agency Science Tech & Res Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells
CN102190731B (zh) * 2010-03-09 2016-01-27 中国科学院上海生命科学研究院 用人工转录因子诱导产生多能干细胞
WO2011140397A2 (en) * 2010-05-05 2011-11-10 The Regents Of The University Of California Office Of The President Stem cell defined media for xeno-free and feeder free conditions and uses thereof
EP2699269A1 (en) * 2011-04-22 2014-02-26 Prosensa Technologies B.V. New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1)

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033828B2 (en) 1989-06-22 2006-04-25 The Salk Institute For Biological Studies Nucleic acid encoding gamma retinoic acid receptor fusion protein
US20090191159A1 (en) * 2007-06-15 2009-07-30 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
WO2010057614A1 (en) 2008-11-21 2010-05-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Reprogramming cells toward a pluripotent state
US20120207744A1 (en) 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same
CA2770412A1 (en) * 2009-08-07 2011-02-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2011142832A2 (en) 2010-05-13 2011-11-17 Whitehead Institute For Biomedical Research Stem cells derived under low oxygen conditions
WO2012012708A1 (en) 2010-07-22 2012-01-26 Regents Of The University Of Minnesota Induced pluripotent stem cells
US9399761B2 (en) 2011-12-05 2016-07-26 Factor Bioscience Inc. Methods of reprogramming cells to a less differentiated state
US9127248B2 (en) 2011-12-05 2015-09-08 Factor Bioscience Inc. Products for transfection and reprogramming
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
US9562218B2 (en) 2011-12-05 2017-02-07 Factor Bioscience Inc. Reprogramming cells to a less differentiated state
US9695401B2 (en) 2011-12-05 2017-07-04 Factor Bioscience Inc. Methods and products for transfection
US9879228B2 (en) 2011-12-05 2018-01-30 Factor Bioscience Inc. Methods and products for transfection
US9969983B2 (en) 2011-12-05 2018-05-15 Factor Bioscience Inc. Methods and products for transfection
WO2013126813A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
US20130302295A1 (en) 2012-05-13 2013-11-14 Allele Biotechnology And Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
WO2013173248A2 (en) 2012-05-13 2013-11-21 Allele Biotechnology And Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
First Office Action in Japanese Patent Application No. 2015-511803, dated Apr. 10, 2017, in 7 pages.
Gai et al., "Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts," Cell Biol. Int., 2009, 33:1184-1193.
Grigoriadis et al., "Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells," Blood, 2010, 115(14):2769-2776.
Hirai et al., "Efficient iPS Cell Production with the MyoD Transactivation Domain in Serum-Free Culture," PLoS One, Mar. 30, 2012, 7(3):1-9.
Hirai, H., et al., "Radical Acceleration of Nuclear Reprogramming by Chromatin Remodeling with the Transactivation Domain of MyoD," Stem Cells, Sep. 2011, vol. 29, No. 9, pp. 1349-1361.
International Search Report and Written Opinion dated Oct. 4, 2013, from corresponding International Patent Application No. PCT/US2013/040814, 10 pages.
International Search Report from International Application No. PCT/US2015/033275, dated Oct. 16, 2015, in 4 pages.
Lamba et al., "Generation, Purification and Transplantation of Photoreceptors Derived from Human Induced Pluripotent Stem Cells," PLoS One, 2010, 5(1):e8763, 9 pages.
Lee et al., "Dual Mechanisms for Repression of the Monomeric Orphan Receptor Liver Receptor Homologous Protein-1 by the Orphan Small Heterodimer Partner," The Journal of Biological Chemistry, Jan. 25, 2002, 277(4):2463-2467.
Liao et al., Cell Research, 18: 600-603, 2008. *
Liew, C-G., "Generation of insulin-producing cells from pluripotent stem cells: from the selection of cell sources to the optimization of protocols", The Review of Diabetic Studies, 2010, vol. 7, No. 2, pp. 82-92.
Lindstrom, et al., "High-Density Microwell Chip for Culture and Analysis of Stem Cells," PLoS One, Sep. 2009, vol. 4, Issue 9, e6997.
Rosa, Allesandro et al., Synthetic mRNAs: Powerful Tools for Reprogramming and Differentiation of Human Cells, Cell Stem Cell, Nov. 5, 2010, vol. 7, No. 5, p. 549-550.
Search Report in Singapore Application No. 11201509368P, dated Nov. 1, 2016, in 2 pages.
Second Office Action in Chinese Patent Application No. 201380025010.4, dated Nov. 18, 2016, in 10 pages.
Song et al., "Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells," Cell Research, 2009, 19(11):1233-1242.
Wang et al., "Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1," PNAS, Nov. 8, 2011, 108(45):18283-18288.
Wang et al., "Reprogramming of mouse and human somatic cells by high-performance engineered factors," EMBO Reports, 2011, 12(4):373-378.
Wang et al., EMBO Reports, 12(4): 2011, Supplemental Materials, pp. 1-25. *
Wang et al., Protein Cell, 3(1): 51-59, Jan. 1, 2012. *
Warren et al., "Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA," Scientific Reports, Sep. 14, 2012, 2:1-7.
Warren et al., Cell Stem Cell, 7(5): 618-630, Nov. 5, 2010. *
Warren, Luigi, et al, "Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA", Cell Stem Cell, Nov. 5, 2010, vol. 7, pp. 618-630.
Weintraub. Gene Dev. 5:1377-1386, 1991. *
Yakubov, Eduard, "Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors", Biochemical and Biophysical Research Communications, 2010, pp. 189-193, vol. 394.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10435711B2 (en) * 2012-05-13 2019-10-08 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA

Also Published As

Publication number Publication date
HK1222675A1 (zh) 2017-07-07
MX2015015840A (es) 2016-08-11
SG10202006695TA (en) 2020-08-28
SG11201509368PA (en) 2015-12-30
US20130302295A1 (en) 2013-11-14
CN105555949A (zh) 2016-05-04
MX2021005715A (es) 2021-07-21
WO2014190361A3 (en) 2015-07-30
WO2014190361A2 (en) 2014-11-27
JP2016521541A (ja) 2016-07-25
JP2021166553A (ja) 2021-10-21
EP2997130A4 (en) 2017-03-01
EP2997130A2 (en) 2016-03-23
HK1224335A1 (zh) 2017-08-18
EP3904504A1 (en) 2021-11-03
JP6971574B2 (ja) 2021-11-24

Similar Documents

Publication Publication Date Title
AU2019203335B2 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
US10435711B2 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
US10155929B2 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
CA2950582C (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
JP2019170405A (ja) 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導
HK40015744A (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK40015744B (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK40013817A (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK40013817B (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK1204005B (zh) 使用合成的信使rna無飼養細胞地衍生人類誘導性多能幹細胞

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC., CALI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WARREN, LUIGI;WANG, JIWU;NI, YUHUI;SIGNING DATES FROM 20140501 TO 20140507;REEL/FRAME:032943/0973

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4